{"title":"Tauroursodeoxycholic acid ameliorates palmitic acid induced endoplasmic reticulum stress and impaired autophagy via IRE1- XBP1-FoxO1 pathway in KGN cells.","authors":"Maosheng Cao, Fengxin Qiao, Qingwei Wang, Jinhong Luo, Yonghong Ju, Xiaodong Wang, Xiang Chen","doi":"10.1016/j.bcp.2025.117377","DOIUrl":null,"url":null,"abstract":"<p><p>Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder among women of childbearing age. Patients with PCOS often have elevated levels of palmitic acid (PA) in their blood and follicular fluid. Granulosa cells (GCs) play crucial roles in follicular development and oocyte maturation. Whether the development of PCOS is related to an increase in PA, which affects GC function, and the underlying mechanisms remain unclear. Tauroursodeoxycholic acid is important for the treatment of metabolic diseases; however, whether it protects GCs remains unknown. In this study, KGN human GCs were treated with PA for 24 h to determine the effects of PA on GCs and elucidate the underlying mechanisms. PA treatment activated the inositol-requiring enzyme 1 pathway and promoted the expression of X-box binding protein 1, which interacted with forkhead box protein O1 and promoted its ubiquitination and degradation. This decreased the levels of autophagy-related gene 7 and inhibited cellular autophagy, leading to impaired mitochondrial function. However, tauroursodeoxycholic acid application reduced inositol-requiring enzyme 1 phosphorylation and promoted autophagy in KGN cells via the X-box binding protein 1-forkhead box protein O1 pathway, thereby restoring the mitochondrial function. Overall, these findings enhance our understanding of the molecular basis of GC impairment in patients with PCOS and provide potential therapeutic targets for their treatment.</p>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":" ","pages":"117377"},"PeriodicalIF":5.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.bcp.2025.117377","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder among women of childbearing age. Patients with PCOS often have elevated levels of palmitic acid (PA) in their blood and follicular fluid. Granulosa cells (GCs) play crucial roles in follicular development and oocyte maturation. Whether the development of PCOS is related to an increase in PA, which affects GC function, and the underlying mechanisms remain unclear. Tauroursodeoxycholic acid is important for the treatment of metabolic diseases; however, whether it protects GCs remains unknown. In this study, KGN human GCs were treated with PA for 24 h to determine the effects of PA on GCs and elucidate the underlying mechanisms. PA treatment activated the inositol-requiring enzyme 1 pathway and promoted the expression of X-box binding protein 1, which interacted with forkhead box protein O1 and promoted its ubiquitination and degradation. This decreased the levels of autophagy-related gene 7 and inhibited cellular autophagy, leading to impaired mitochondrial function. However, tauroursodeoxycholic acid application reduced inositol-requiring enzyme 1 phosphorylation and promoted autophagy in KGN cells via the X-box binding protein 1-forkhead box protein O1 pathway, thereby restoring the mitochondrial function. Overall, these findings enhance our understanding of the molecular basis of GC impairment in patients with PCOS and provide potential therapeutic targets for their treatment.
期刊介绍:
Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.
The journal''s target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.
All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.
While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.